Fine Chemicals Groups conference, London, 7 June 2007
Adverse safety findings remains one of the major reasons for candidate drugs failing to reach the market. It has also become an issue with existing medications with some recent high profile market withdrawals. This meeting was designed to allow chemists to gain a broad understanding of a range of key, current issues within the drug safety arena. The meeting was recommended both for chemists just beginning their careers within the pharmaceutical industry, or more experienced medicinal chemists wanting to gain a more detailed understanding of these issues.
| Programme | ||
| 10.00 | Introduction and Welcome David Lathbury, AstraZeneca | |
| 10.05 | Overview of Safety Assessment, Principles, Mechanisms, Structure and Toxicity (pdf 60Kb) Nigel Rogers, PresidX | |
| 11.05 | Prediction of Drug-Drug Interactions arising from CYP-Inhibition Iain Martin, Organon | |
| 11.50 | Reactive Metabolites in Lead Optimisation Graham Somers, GlaxoSmithKline | |
| Session Chairman: Chris Hill, Organon | ||
| 13.45 | Safety Testing of Genotoxic Impurities (pdf 700Kb) Mike O'Donovan, AstraZeneca | |
| 14.30 | Genotoxic and Non-Genotoxic Impurities: Identification, Qualification, Testing and Risk Assessment Considerations (pdf 300Kb) Charles Humfrey, AstraZeneca | |
| Session Chairman: Alan Brown, Pfizer | ||
| 15.45 | Ongoing Challenges in Cardiovascular Safety - a Continued Source of Early Compound Attrition Derek Leishman, Lilly | |
| 16.30 | Integrating Molecular Toxicology Earlier in the Drug Development Process (pdf 830Kb) Fiona Spence, Pfizer (delivered by Jonathan Hitchcock) | |
Visit Blog